BY101298 Capsules

DRUG2 trials

Sponsors

Chengdu Baiyu Pharmaceutical Co., Ltd.

Conditions

Solid Tumor, Adult

Phase 1

A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors

Active, not recruitingNCT06462716

Chengdu Baiyu Pharmaceutical Co., Ltd.Solid Tumor, Adult

Start: 2023-04-25End: 2025-06-30Target: 36Updated: 2025-04-13

A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors

TerminatedNCT06524804

Chengdu Baiyu Pharmaceutical Co., Ltd.Solid Tumor, Adult

Start: 2024-05-15End: 2024-10-18Updated: 2024-12-18